Bayer will appear before a federal judge to dismantle ongoing litigation involving its Roundup weedkiller. The company inherited these extensive legal battles through its acquisition of Monsanto.
A favorable ruling could significantly reduce legal liabilities and financial pressure from thousands of cancer-related claims. This litigation remains a primary concern for investors and continues to weigh on Bayer’s stock performance.